220 related articles for article (PubMed ID: 26508513)
1. Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel.
Herold BC; Chen BA; Salata RA; Marzinke MA; Kelly CW; Dezzutti CS; McGowan I; Galaska B; Levy L; Piper JM; Hillier S; Hendrix CW
Clin Infect Dis; 2016 Feb; 62(3):375-382. PubMed ID: 26508513
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Justman JE; Nair GL; Hendrix CW; Piper JM; Marzinke MA; Dai JY; Pan Z; Galaska B; Levy L; Schwartz JL; Balar B; Kunjara Na Ayudhya RP; Mushamiri I; McGowan I; Dezzutti CS;
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):175-182. PubMed ID: 29767639
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05).
Robinson JA; Marzinke MA; Fuchs EJ; Bakshi RP; Spiegel HML; Coleman JS; Rohan LC; Hendrix CW
J Acquir Immune Defic Syndr; 2018 Feb; 77(2):175-182. PubMed ID: 29135651
[TBL] [Abstract][Full Text] [Related]
4. FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir.
Bunge KE; Dezzutti CS; Hendrix CW; Marzinke MA; Spiegel HML; Moncla BJ; Schwartz JL; Meyn LA; Richardson-Harman N; Rohan LC; Hillier SL
J Int AIDS Soc; 2018 Aug; 21(8):e25156. PubMed ID: 30101439
[TBL] [Abstract][Full Text] [Related]
5. Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.
Dobard CW; Taylor A; Sharma S; Anderson PL; Bushman LR; Chuong D; Pau CP; Hanson D; Wang L; Garcia-Lerma JG; McGowan I; Rohan L; Heneine W
J Infect Dis; 2015 Dec; 212(12):1988-95. PubMed ID: 26071566
[TBL] [Abstract][Full Text] [Related]
6. Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.
Seifert SM; Glidden DV; Meditz AL; Castillo-Mancilla JR; Gardner EM; Predhomme JA; Rower C; Klein B; Kerr BJ; Guida LA; Zheng JH; Bushman LR; Anderson PL
Clin Infect Dis; 2015 Mar; 60(5):804-10. PubMed ID: 25409469
[TBL] [Abstract][Full Text] [Related]
7. Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring.
Koss CA; Liu AY; Castillo-Mancilla J; Bacchetti P; McHugh C; Kuncze K; Morrow M; Louie A; Seifert S; Okochi H; MaWhinney S; Gandhi M; Anderson PL
AIDS; 2018 Sep; 32(15):2189-2194. PubMed ID: 30212404
[TBL] [Abstract][Full Text] [Related]
8. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
[TBL] [Abstract][Full Text] [Related]
9. Topical tenofovir protects against vaginal simian HIV infection in macaques coinfected with Chlamydia trachomatis and Trichomonas vaginalis.
Makarova N; Henning T; Taylor A; Dinh C; Lipscomb J; Aubert R; Hanson D; Phillips C; Papp J; Mitchell J; McNicholl J; Garcia-Lerma GJ; Heneine W; Kersh E; Dobard C
AIDS; 2017 Mar; 31(6):745-752. PubMed ID: 28060011
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC
AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514
[TBL] [Abstract][Full Text] [Related]
11. A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).
Mcgowan I; Cranston RD; Duffill K; Siegel A; Engstrom JC; Nikiforov A; Jacobson C; Rehman KK; Elliott J; Khanukhova E; Abebe K; Mauck C; Spiegel HM; Dezzutti CS; Rohan LC; Marzinke MA; Hiruy H; Hendrix CW; Richardson-Harman N; Anton PA
PLoS One; 2015; 10(5):e0125363. PubMed ID: 25942472
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa.
Mallayasamy S; Chaturvedula A; Fossler MJ; Sale M; Goti V; Bumpus NN; Marzinke MA; Hendrix CW; Haberer JE;
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182536
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques.
Dobard CW; Sharma S; Cong ME; West R; Makarova N; Holder A; Pau CP; Hanson DL; Novembre FJ; Garcia-Lerma JG; Heneine W
Retrovirology; 2015 Aug; 12():69. PubMed ID: 26253002
[TBL] [Abstract][Full Text] [Related]
14. A Mechanistic In Vivo/Ex Vivo Pharmacokinetic-Pharmacodynamic Model of Tenofovir for HIV Prevention.
Jayachandran P; Garcia-Cremades M; Vučićević K; Bumpus NN; Anton P; Hendrix C; Savić R
CPT Pharmacometrics Syst Pharmacol; 2021 Mar; 10(3):179-187. PubMed ID: 33547874
[TBL] [Abstract][Full Text] [Related]
15. Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel.
Thurman AR; Chandra N; Yousefieh N; Kimble T; Anderson SM; Cottrell M; Sykes C; Kashuba A; Schwartz JL; Doncel GF
J Acquir Immune Defic Syndr; 2018 May; 78(1):82-92. PubMed ID: 29424790
[TBL] [Abstract][Full Text] [Related]
16. Nondaily preexposure prophylaxis for HIV prevention.
Anderson PL; García-Lerma JG; Heneine W
Curr Opin HIV AIDS; 2016 Jan; 11(1):94-101. PubMed ID: 26633641
[TBL] [Abstract][Full Text] [Related]
17. Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.
Himes SK; Wu JW; Jacobson DL; Tassiopoulos K; Hazra R; Kacanek D; Van Dyke RB; Rich KC; Siberry GK; Huestis MA;
Pediatr Infect Dis J; 2015 Aug; 34(8):851-7. PubMed ID: 25961889
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits.
Clark MR; Friend DR
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1458-66. PubMed ID: 22394281
[TBL] [Abstract][Full Text] [Related]
19. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
Hendrix CW; Chen BA; Guddera V; Hoesley C; Justman J; Nakabiito C; Salata R; Soto-Torres L; Patterson K; Minnis AM; Gandham S; Gomez K; Richardson BA; Bumpus NN
PLoS One; 2013; 8(1):e55013. PubMed ID: 23383037
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel.
Keller MJ; Madan RP; Torres NM; Fazzari MJ; Cho S; Kalyoussef S; Shust G; Mesquita PM; Louissaint N; Chen J; Cohen HW; Diament EC; Lee AC; Soto-Torres L; Hendrix CW; Herold BC
PLoS One; 2011 Jan; 6(1):e16475. PubMed ID: 21283552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]